Oregon Psilocybin Services Act (Measure 109)

Measure 109 Implementation

Ballot Measure 109 (2020) directs the Oregon Health Authority (OHA) — after a two-year development period from January 1, 2021 to December 31, 2022 — to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products and the provision of psilocybin services. During the two year development period OHA will work with the Oregon Psilocybin Advisory Board to establish rules and regulations implementing Measure 109 and the use of psilocybin products and services.

OHA will not be issuing licenses or accepting applications related to the manufacture, sale and purchase of psilocybin products and the provision of psilocybin services until January 2, 2023.

Email inquiries: oha.psilocybin@dhsoha.state.or.us

Read Measure 109 - The Oregon Psilocybin Services Act

Oregon Psilocybin Advisory Board

Established by Ballot Measure 109 (2020), the Oregon Psilocybin Advisory Board makes recommendations to OHA on available scientific studies and research on the safety and efficacy of psilocybin in treating mental health conditions, and makes recommendations on the requirements, specifications and guidelines for providing psilocybin services in Oregon. The Board will also develop a long-term strategic plan for ensuring that psilocybin services will become and remain a safe, accessible and affordable therapeutic option for all persons 21 years of age and older in this state for whom psilocybin may be appropriate; and monitor and study federal laws, regulations and policies regarding psilocybin.

Advisory Board Meetings

March 31, 2021, 1:00 - 4:00 pm
Meeting Agenda
Meeting Minutes
Complete PAB Meeting 3.31.21.m4a

April 28, 2021, 1:00 - 4:00 pm
Meeting Agenda
Meeting Minutes
Complete PAB Meeting 4.28.21.m4a

May 26, 2021, 1:00 - 4:00 pm
Meeting Agenda
Complete PAB Meeting 5.26.21.m4a

June 23, 2021, 1:00 - 4:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Agenda TBD

July 28, 2021, 1:00 - 4:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Agenda TBD

August 25, 2021, 1:00 - 4:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Agenda TBD

Subcommittee Meetings

Training Subcommittee

April 23, 2021, 1:00 - 3:00
Complete PAB-TS Meeting 4.23.21.m4a

May 7, 2021, 1:00 - 3:00 pm

Complete PAB-TS Meeting 5.7.21.m4a

May 14, 2021, 1:00 - 3:00 pm

Meeting Notes
Complete PAB-TS Meeting 5.14.21.m4a

May 21, 2021, 1:00 - 3:00 pm
Meeting Notes

Complete PAB-TS Meeting 5.21.21.m4a

May 28, 2021, 1:00 - 3:00 pm

Complete PAB-TS Meeting 5.28.21.m4a

June 4, 2021, 1:00 - 3:00 pm
Meeting Agenda
Complete PAB-TS Meeting 6.4.21.m4a

June 11, 2021, 1:00 - 3:00 pm
Meeting Agenda
Complete PAB-TS Meeting 6.11.21.m4a

June 18, 2021, 1:00 - 3:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

June 25, 2021, 1:00 - 3:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

July 2, 2021, 1:00 - 3:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Research Subcommittee

April 14, 2021
Meeting Notes

Complete PAB-RS Meeting 4.14.21.m4a

April 29, 2021
Meeting Notes

Complete PAB-RS Meeting 4.29.21.m4a

May 6, 2021, 1:00-2:00 pm
Meeting Notes

Complete PAB-RS Meeting 5.6.21.m4a

May 13, 2021, 1:00 - 2:00 pm
Meeting Notes
Complete PAB-RS Meeting 5.13.21.m4a

May 20, 2021, 1:00 - 2:00 pm
Meeting Notes

Complete PAB-RS Meeting 5.20.21.m4a

May 27, 2021, 1:00 - 2:00 pm
Meeting Notes
Complete PAB-RS Meeting 5.27.21.m4a

June 3, 2021, 1:00 - 2:00 pm
Meeting Notes
Complete PAB-RS Meeting 6.3.21.m4a

June 10, 2021, 1:00 - 2:30 pm
Meeting Agenda
Meeting Notes
Complete PAB-RS Meeting 6.10.21.m4a

June 17, 2021, 1:00 - 2:30 pm
https://www.zoomgov.com/j/16018821728
Complete PAB-RS Meeting 6.17.21.m4a

June 24, 2021, 1:00 - 2:30 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

July 1, 2021, 1:00 - 2:30 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Products Subcommittee

May 14, 2021, 3:00-5:00 pm
Meeting Agenda (draft 5/7/21)
Meeting Minutes
Complete PAB-PS Meeting 5.14.21

May 27, 2021, 11:00 am - 1:00 pm
Meeting Agenda
Meeting Minutes
Complete PAB-PS Meeting 5.27.21.m4a

June 10, 2021, 11:00 am - 1:00 pm
Meeting Agenda
Meeting Minutes
Complete PAB-PS Meeting Audio 6.10.21.m4a
Complete PAB-PS Meeting Video 6.10.21

June 24, 2021, 11:00 am - 1:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Meeting Agenda

July 8, 2021, 11:00 am - 1:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Licensing Subcommittee

May 13, 2021, 2:00 - 4:00 pm
Meeting Notes
Complete PAB-LS Meeting 5.13.21

May 24, 2021, 5:00 - 7:00 pm
Meeting Minutes
Complete PAB-LS Meeting 5.24.21.m4a

June 17, 2021, 4:00 - 6:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728
Meeting Agenda

June 24, 2021, 4:00 - 6:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

July 1, 2021, 4:00 - 6:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

July 8, 2021, 4:00 - 6:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Equity Subcommittee

May 12, 2021 4:00 - 5:00 pm
Meeting Agenda
Meeting Notes
Complete PAB-ESC Meeting 5.12.21.m4a

May 19, 2021 4:00 - 5:00 pm
Complete PAB-ESC Meeting 5.19.21.m4a

June 4, 2021 3:00 - 5:00 pm
Meeting Agenda
Complete PAB-ESC Meeting 6.4.21.m4a

June 18, 2021 3:00 - 5:00 pm
https://www.zoomgov.com/j/16018821728
Meeting ID: 160 1882 1728

Scientific Literature Review

Safety and efficacy of psilocybin in treating mental health conditions

By June 30, 2021, the board will submit its findings and recommendations to the Oregon Health Authority on the available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

By July 31, 2021, and from time to time after such date, the Oregon Health Authority shall publish and distribute to the public available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end of-life psychological distress.